Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

NCT05208047 is registered in ClinicalTrials.gov with Cogent Biosciences, Inc. as lead sponsor.

NCT NCT05208047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05208047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
Lead sponsor
Cogent Biosciences, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
April 14, 2022
Completion date
January 31, 2030
Enrollment
482 (estimated)
Sites
126

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastrointestinal stromal tumors, metastatic cancer